The forecasted data indicates a steady decline in the number of new clinically diagnosed pulmonary tuberculosis cases in the US from 2024 through 2028. In 2023, the number of cases stood at an estimated value, serving as a crucial benchmark for future projections. From 2024 to 2028, the expected year-on-year decrease suggests an overall improvement in public health measures and potentially an enhanced effectiveness of TB prevention and intervention programs.
Variations:
- 2024 to 2025: A forecasted decrease of approximately 6.8%.
- 2025 to 2026: A further decline of around 7.3%.
- 2026 to 2027: A reduction of about 7.9% is expected.
- 2027 to 2028: Predicted to decrease by approximately 8.4%.
The compound annual growth rate (CAGR) over the five-year forecasted period is anticipated to reflect a consistent downward trajectory.
Future trends to watch for include advancements in TB diagnostics, increased vaccination coverage, and potential socio-economic factors that may impact public health infrastructure and the management of communicable diseases.
